drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
An autologous anti-CD20 chimeric antigen receptor T-cell (CAR-T) therapy in which a patient’s T cells are engineered ex vivo to express a CAR that binds CD20 on B cells; CAR activation triggers cytotoxic activity and cytokine release to eliminate CD20-positive malignant B cells, with expected on-target B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered ex vivo to express a chimeric antigen receptor that binds CD20 on B cells; CAR engagement activates T-cell cytotoxicity and cytokine release to eliminate CD20-positive malignant B cells, with expected on-target B-cell aplasia.
drug_name
JNJ-90009530 (C-CAR066)
nct_id_drug_ref
NCT05784441